PMID- 22212505 OWN - NLM STAT- MEDLINE DCOM- 20120613 LR - 20220310 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 139 IP - 3 DP - 2012 Feb 15 TI - Antidiabetic effect of total saponins from Entada phaseoloides (L.) Merr. in type 2 diabetic rats. PG - 814-21 LID - 10.1016/j.jep.2011.12.025 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: The seed of Entada phaseoloides (L.) Merr. (Entada phaseoloides) has been long used as an effective herb for the treatment of Diabetes mellitus by Dai people, one of the Chinese ethnic minorities. Saponin is an abundant type of secondary metabolic products in the seed of this plant. The aim of this study is to evaluate the potential therapeutic effects of total saponins from Entada phaseoloides (TSEP) in experimental type 2 Diabetes mellitus (T2DM) rats. MATERIALS AND METHODS: T2DM rats were induced by high-fat diet and low-dose streptozotocin (STZ). Then different oral doses of TSEP (25, 50 and 100 mg/kg) were administrated to T2DM rats for 21 days. For comparison, a standard antidiabetic drug, metformin (200 mg/kg), was used as a positive control drug. Then the relative biochemical analysis and histopathological examination were made to evaluate the antidiabetic effect of TSEP. RESULTS: TSEP dramatically reduced fasted blood glucose and serum insulin levels and alleviates hyperglycemia associated oxidative stress in T2DM rats. Moreover, a significantly hypolipidemic effect and an improvement in tissue steatosis could be observed after TSEP administration. Further investigations revealed a possible anti-inflammation effect of TSEP by examining serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP). The effects of TSEP exhibited a dose-dependent manner and were comparable to metformin. CONCLUSION: Our present study demonstrates both hypoglycemic and hypolipidemic activities of TSEP in T2DM rats, which support its antidiabetic property. This work also implies a possibility that TSEP exerts its therapeutic effect through repressing chronic inflammation responses. CI - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved. FAU - Zheng, Tao AU - Zheng T AD - College of Pharmacy, South-Central University for Nationalities, Wuhan, PR China. FAU - Shu, Guangwen AU - Shu G FAU - Yang, Zhanzhan AU - Yang Z FAU - Mo, Shasha AU - Mo S FAU - Zhao, Yin AU - Zhao Y FAU - Mei, Zhinan AU - Mei Z LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20111228 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Blood Glucose) RN - 0 (Hypoglycemic Agents) RN - 0 (Hypolipidemic Agents) RN - 0 (Inflammation Mediators) RN - 0 (Insulin) RN - 0 (Plant Extracts) RN - 0 (Saponins) RN - 5W494URQ81 (Streptozocin) RN - 9100L32L2N (Metformin) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology/therapeutic use MH - Blood Glucose/*metabolism MH - Diabetes Mellitus, Experimental/blood/*drug therapy/pathology MH - Diet, High-Fat/adverse effects MH - Dose-Response Relationship, Drug MH - Fabaceae/*chemistry MH - Fasting MH - Hypoglycemic Agents/pharmacology/*therapeutic use MH - Hypolipidemic Agents/pharmacology/therapeutic use MH - Inflammation Mediators/blood MH - Insulin/blood MH - Male MH - Metformin/pharmacology MH - Oxidative Stress/drug effects MH - *Phytotherapy MH - Plant Extracts/pharmacology/*therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Saponins/pharmacology/*therapeutic use MH - Seeds MH - Streptozocin EDAT- 2012/01/04 06:00 MHDA- 2012/06/14 06:00 CRDT- 2012/01/04 06:00 PHST- 2011/08/12 00:00 [received] PHST- 2011/12/06 00:00 [revised] PHST- 2011/12/13 00:00 [accepted] PHST- 2012/01/04 06:00 [entrez] PHST- 2012/01/04 06:00 [pubmed] PHST- 2012/06/14 06:00 [medline] AID - S0378-8741(11)00903-2 [pii] AID - 10.1016/j.jep.2011.12.025 [doi] PST - ppublish SO - J Ethnopharmacol. 2012 Feb 15;139(3):814-21. doi: 10.1016/j.jep.2011.12.025. Epub 2011 Dec 28.